Articles related to SHARED DECISION-MAKING

Reevaluation of major hormone therapy studies has prompted renewed discussion about menopause treatment in breast cancer survivors. Emerging interpretation of older trial data suggests treatment risks may vary by patient characteristics and hormone formulation rather than applying uniformly across all populations.

Older adults with diabetes and frailty frequently experience overtreatment despite individualized glycemic goals that prioritize safety over intensive control. A narrative review highlights deprescribing strategies, relaxed glycemic targets, and medication adjustments intended to reduce hypoglycemia, falls, and treatment burden.

ACOG has revised its approach to postmenopausal bleeding evaluation, recommending combined transvaginal ultrasonography and endometrial sampling for most patients at initial presentation. The update reflects rising endometrial cancer incidence, evolving evidence on cancer subtypes, and recognized limitations of ultrasound-only evaluation.

A European Heart Journal debate revisits whether surgical aortic valve replacement should remain the preferred approach for patients with aortic stenosis and life expectancy beyond five years. Long-term durability and late procedural outcomes continue to shape the discussion.

A case-based application of FRESCO trial data positions fruquintinib as a third-line option in KRAS-mutant metastatic colorectal cancer, while emphasizing treatment decisions shift toward disease control and quality of life after multiple prior lines.

A clinician review outlined how diagnostic confidence, staging, genetic risk, and imaging features inform patient selection for amyloid-targeting Alzheimer’s therapies.